Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
770.960.29%
QQQ
718.540.12%
BTC/USD
79737.051.8936%
DIA
534.640.43%
GLD
406.940.8%
TLT
82.420.43%

TScan Therapeutics Inc

TCRXNASDAQ
Trade with Public
Trade with Public
$0.3800
0.00912.45%
Last update: Sep 4, 9:25 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

TScan Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for TScan Therapeutics (TCRX).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

3Buy
3Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$8Upside to Avg. PT+1918.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 3, 2026WedbushDavid NierengartenDowngradeOutperform→Neutral$5→$1
Sep 2, 2026NeedhamGil BlumDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target

Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5

Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved